Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Account Payables

Amounts the company owes suppliers for goods and services received.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 130.1% from a year ago

Account payables stood at $9.65M at the end of Q1 FY2026, up 130.1% from a year earlier and up 18.9% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Account payables amounted to 3.7% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +130.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.65M+18.9% QoQ
Last fiscal yearDec 2025
$8.11M+78.5% YoY
Year agoMar 2025
$4.19M+130.1% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+130.1%——
1 year+78.5%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
8.11M USD
Year-over-year change
+78.5%
4-year CAGR
-11.6%

Account Payables vs competitors

How TNXP compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +130.1% is the 3rd highest of 10, against a peer median of +7.8%.
  • Account payables amounts to 3.7% of total assets for TNXP, versus a peer median of 2.0%.
TNXP Competitors
Account Payables for TNXP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPHAInnate Pharma S.A.Dec 2025€15.04M EUR+89.8%+3.3%24.0%
FBRXForte Biosciences, Inc.Mar 2026$13.08M USD+160.5%+105.4%19.5%
MISTMilestone Pharmaceuticals Inc.Mar 2026$10.02M USD+320.4%+35.6%5.2%
TNXPTonix Pharmaceuticals Holding Corp.Mar 2026$9.65M USD+130.1%+0.2%3.7%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$6.59M USD+127.0%+18.1%4.5%
FATEFate Therapeutics, Inc.Mar 2026$3.28M USD-21.8%-31.5%1.2%
MCRBSeres Therapeutics, Inc.Mar 2026$2.34M USD+7.8%-54.1%2.0%
NKTXNkarta, Inc.Mar 2026$1.59M USD+6.4%+5.9%0.4%
AVTXAvalo Therapeutics, Inc.Mar 2026$356K USD-47.7%-63.8%0.4%
ELTXElicio Therapeutics, Inc.Mar 2026$272K USD-93.3%-37.9%1.2%
Peer median (excluding TNXP) —+7.8%+3.3%2.0%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents178.66M120.23M24.95M98.78M207.64M
Short-term Investments00000
Net Receivables7.73M8.04M4.59M7.9M9.76M
Inventory0014.15M8.41M6.01M
Other Current Assets1.18M1.23M2.43M1.46M5.47M
Total Current Assets189.05M130.78M47.77M119M228.88M
Property, Plant & Equipment (Net)51.47M94.53M94.85M42.82M46M
Goodwill00965K00
Intangible Assets120K120K9.74M120K120K
Long-term Investments240K00904K2.18M
Tax Assets(240K)0000
Other Non-current Assets259K264K1.13M47K0
Total Non-current Assets51.85M94.91M106.69M43.89M48.3M
Total Assets240.9M225.69M154.46M162.89M277.17M
Account Payables13.28M8.07M3.78M4.55M8.11M
Short-term Debt002.35M00
Tax Payables00000
Deferred Revenue2.83M3.27M2.98M1.82M3.43M
Other Current Liabilities2.25M3.65M5.14M7.32M11.26M
Total Current Liabilities21.72M18.18M18.88M18.31M30.84M
Long-term Debt006.56M4.67M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0022.86M00
Total Non-current Liabilities467K328K30.05M5.03M1.18M
Total Liabilities22.18M18.51M48.93M23.33M32.02M
Common Stock496K12K59K4K13K
Retained Earnings(359.82M)(470.04M)(600.66M)(730.69M)(854.72M)
Accumulated OCI(92K)(167K)(232K)(255K)(289K)
Other Stockholders Equity480K0000
Minority Interest00000
Total Equity218.72M207.18M105.53M139.56M245.15M
Total Debt956K760K9.81M5.3M1.31M
Net Debt(177.7M)(119.47M)(15.14M)(93.48M)(206.33M)

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.